DataVXChemNanoMatPaper
journal article·2019-07

Organosilica Nanoparticles for Gemcitabine Monophosphate Delivery in Cancer Cells

Morgane Daurat, Saher Rahmani, Roza Bouchal, Alia Akrout, Jelena Budimir, Christophe Nguyen, Clarence Charnay, Yannick Guari, Sébastien Richeter, Laurence Raehm, Nadir Bettache, Magali Gary‐Bobo, Jean‐Olivier Durand, Peter Hesemann

ChemNanoMat· Volume 5· Issue 7
Publisher page
Source abstract

Abstract

Abstract Organosilica nanoparticles hold great promise for nanomedicine applications. These nanoparticles are synthesized from polytrialkoxysilylated precursors without any silica source. In this work we present two kinds of organosilica nanoparticles with either amine or ammonium walls constituting their structure. Both types of nanoparticles are very efficient for gemcitabine monophosphate delivery, a small hydrophilic anticancer drug whose encapsulation is still a challenge. The nanoparticles are endocytosed by MCF‐7 breast cancer cells as monitored by confocal microscopy. They are efficient and lead to 60% cancer cell death.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Metal complexes synthesis and properties · Mesoporous Materials and Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institut des Biomolécules Max Mousseron UMR 5247 CNRS, UM-Faculté de Pharmacie Avenue Charles Flahault 34093 Montpellier cedex 05 France

NanoMedSyn Institut des Biomolécules Max Mousseron UMR 5247 CNRS, UM-Faculté de Pharmacie Avenue Charles Flahault 34093 Montpellier cedex 05 France

Institut Charles Gerhardt Montpellier UMR-5253 CNRS-UM-ENSCM cc 1701 Place Eugène Bataillon 34095 Montpellier cedex 05 France

References (35)

Show source-provided references
1. 10.1039/C6NR06862F10.1039/C6NR06862F ↗
2. 10.1515/ntrev-2012-000510.1515/ntrev-2012-0005 ↗
3. 10.1002/adma.20160463410.1002/adma.201604634 ↗
4. 10.1016/j.biomaterials.2016.03.01910.1016/j.biomaterials.2016.03.019 ↗
5. 10.1002/adma.20150514710.1002/adma.201505147 ↗
6. 10.1039/C5NR05649G10.1039/C5NR05649G ↗
7. 10.1002/adhm.20170083110.1002/adhm.201700831 ↗
8. 10.1021/acsbiomaterials.6b0011110.1021/acsbiomaterials.6b00111 ↗
9. 10.1016/j.msec.2015.12.09610.1016/j.msec.2015.12.096 ↗
10. 10.1021/acsnano.5b0051010.1021/acsnano.5b00510 ↗
11. 10.1016/j.jconrel.2016.03.03010.1016/j.jconrel.2016.03.030 ↗
12. 10.1007/s11051-015-2929-110.1007/s11051-015-2929-1 ↗
13. 10.1016/j.ijpharm.2014.11.00910.1016/j.ijpharm.2014.11.009 ↗
14. 10.1002/ejoc.20110003610.1002/ejoc.201100036 ↗
15. 10.3109/1061186X.2015.107329410.3109/1061186X.2015.1073294 ↗
16. 10.1002/anie.20170734610.1002/anie.201707346 ↗
17. 10.1016/j.jconrel.2015.01.02610.1016/j.jconrel.2015.01.026 ↗
18. 10.1021/acs.molpharmaceut.6b0046610.1021/acs.molpharmaceut.6b00466 ↗
19. 10.1021/jacs.6b0248610.1021/jacs.6b02486 ↗
20. 10.1016/j.actbio.2016.01.03910.1016/j.actbio.2016.01.039 ↗
21. 10.1038/mt.2013.12010.1038/mt.2013.120 ↗
22. 10.1016/j.biomaterials.2013.07.05010.1016/j.biomaterials.2013.07.050 ↗
23. 10.1016/j.biomaterials.2013.01.06310.1016/j.biomaterials.2013.01.063 ↗
24. 10.1002/adfm.20140107610.1002/adfm.201401076 ↗
25. 10.1016/j.jconrel.2014.03.01610.1016/j.jconrel.2014.03.016 ↗
26. 10.1021/acsami.7b0726410.1021/acsami.7b07264 ↗
27. 10.1021/acsnano.5b0430610.1021/acsnano.5b04306 ↗
28. 10.1002/adma.20140193110.1002/adma.201401931 ↗
29. 10.1039/b925352a10.1039/b925352a ↗
30. 10.1039/c1jm10422e10.1039/c1jm10422e ↗
31. 10.1021/acs.jpcc.6b0945710.1021/acs.jpcc.6b09457 ↗
32. 10.1039/C6NJ01473A10.1039/C6NJ01473A ↗
33. 10.1016/j.jcis.2016.07.06910.1016/j.jcis.2016.07.069 ↗
34. 10.1016/j.seppur.2017.07.06710.1016/j.seppur.2017.07.067 ↗
35. 10.1021/acsanm.8b0002010.1021/acsanm.8b00020 ↗